Currently Viewing:
Newsroom
Currently Reading
ELOQUENT-3: Adding Elotuzumab to Pomalidomide, Dexamethasone Improves PFS in R/R Multiple Myeloma
December 08, 2018 – David Bai, PharmD
Studies Show Medicaid Expansion Is Improving Health, While Jury Still Out on Chronic Disease
December 07, 2018 – Mary Caffrey
Continuous Infusion of Recombinant Activated Factor VII Safe, Effective in Management of Congenital Hemophilia
December 07, 2018 – Jackie Syrop
Study Identifies COPD Patient Subgroup Who Benefit Most From Roflumilast
December 07, 2018 – Alison Rodriguez
Researchers Demonstrate Efficacy of EEG-Based Test for Measuring Pain
December 07, 2018 – Alison Rodriguez
European Stakeholders Appeal EPO Ruling to Uphold Gilead's Sofosbuvir Patent
December 07, 2018 – Samantha DiGrande
5 Things to Know About Getting the Flu Shot
December 07, 2018 – Samantha DiGrande
CMS Finalizes Risk-Adjustment Rule for 2018 Benefit Year
December 07, 2018 – Allison Inserro
International Consensus on Timely Care for Multiple Sclerosis
December 07, 2018 – David Bai, PharmD

What We're Reading: Short-Term Plan Vote; Support for Rituxan Biosimilar; Centene Expands ACA Footprint

AJMC Staff
Senate Democrats were 1 vote short of overturning the Trump administration's expansion of short-term health plans; Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel; Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019.

Senate Democrats Vote on Short-Term Insurance Plans

Democrats forced a vote on the Trump administration’s expansion of short-term health insurance plans that do not have to comply with Affordable Care Act (ACA) regulations. However, they fell short of overturning the expansion of these plans by just 1 vote, according to The Washington Post. Democrats voted unanimously to overturn the administration rule and also brought in a vote from Senator Susan Collins, R-Maine, but they would have needed a second Republican vote in order to pass the legislation. In addition, President Donald Trump had already threatened to veto the measure if it reached his desk.

 

FDA Panel Votes in Favor of Rituxan Biosimilar

Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel. Reuters reported that the panel ruled Celltrion’s biosimilar was highly similar to the reference biologic. In February, the FDA had declined to approve the proposed biosimilar, citing a manufacturing issue. The FDA usually follows the advice of its advisory panels.

 

Centene Will Expand ACA Footprint

As more insurers are able to find profits in the ACA marketplaces, they have been expanding their participation. Insurer Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019, according to Fierce Healthcare. The company had increased revenue 13% at the end of the first quarter in 2018. In June, Molina Healthcare and Oscar Insurance reported they were entering new states.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!